167 results
Page 2 of 9
8-K
EX-99.3
71t9gfebh m767d
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.1
2dt4wjrvuv o0
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
93be1
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
1pp4443n
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
hd64gbo
14 Aug 23
Other Events
8:00am
8-K
EX-99.1
1gbj8pesqr1 wpl
10 Aug 23
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
7:03am
8-K
EX-99.1
0w8laoke82fpsq
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
EX-99.2
c5l5so hpil
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
EX-99.1
xxk12fdi ssogsq
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm
8-K
EX-99.1
qk2xg6z676o
15 May 23
Results of Operations and Financial Condition
7:05am
8-K
EX-99.2
0hxgwlfh
15 May 23
Results of Operations and Financial Condition
7:05am
8-K
EX-99.2
yuu7xouh4p48 ab9a
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
lxwvt8ma3pk1g6m 496t
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am
8-K
8uac3cr5pqr9mjq
14 Sep 22
Entry into a Material Definitive Agreement
9:01am